Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

Share Price is delayed by 15 minutes
Get Live Data
12.60    -0.05 (-0.40%)
Bid:
12.60
Ask:
12.95
Spread: 0.35 (2.778%)
Market Cap: £42.85m
BVC Live PriceLast checked at - London Stock Exchange

Intraday Batm Advanced Share Chart

Trading and Business Update

7 Jan 2014 07:00

RNS Number : 0255X
BATM Advanced Communications Ld
07 January 2014
 



7 January 2014

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading and Business Update

 

BATM Advanced Communications Limited (LSE: BVC; TASE: BATM), a leading provider of real-time technologies for the networked telecoms and medical laboratory equipment markets, provides the following trading and business update for the 12 months ended 31 December 2013 ahead of its full year results announcement on 25 February 2014.

 

The Group anticipates that revenue for full year 2013 will be in line with expectations at approximately $114m. This reflects a better-than-expected performance in the Medical division and a Telecom division that is stabilizing and at the beginning of its recovery process. Specifically, in the fourth quarter, the Medical division's revenue increased by 20% over the comparative period in 2012. This was due to growth in all three businesses of the division, including the commencement of the contribution to revenue from the medical sterilization unit being marketed by a leading vendor in the US. The diagnostics business performed well, including but not limited to the first sales of its HIV kits, and increased its contribution to revenue in the fourth quarter compared with the equivalent period in 2012.

 

The Telecom division received less-than-expected revenue from clients in the US and Latin America in the fourth quarter, and suffered from a 10% appreciation of the Israeli shekel against the US dollar during 2013 compared with 2012. Whilst the decrease in revenue in the Telecom division was offset by the performance of the Medical division, the latter has lower profit margins than the Telecom division and consequently, as a result of the higher revenue contribution from the Medical division, the Group expects EBITDA (before share-based payments) for 2013 to be below market expectations at approximately $2m-$2.5m.

 

For 2014, the Medical division is expected to continue to expand globally with an increased focus on both diagnostics and medical waste solutions. The Group is expanding production capacity to cope with the increased orders in the sterilization and the diagnostics businesses. As a result, the Group expects to maintain the division's momentum of 2013 into 2014, with higher sales and improving gross margins.

 

Whilst the Telecom division continues to be vulnerable to macro-economic conditions, including that network operators are deliberating over upgrading their systems and the appreciation of the Israeli shekel, the Group expects that trading in this division will firmly stabilise after the first quarter of 2014 and progressively improve thereafter. In the final quarter, Mr Ariel Efrati, who had joined the Group in September 2013 as Chief Operating Officer of BATM, took over as Managing Director of the Telecom division and has commenced driving the business forward in line with the division's new strategy, introduced in Q3 2013, of focusing on Tier 1 and larger customers as well as providing existing customers with state-of-the-art networking equipment.

 

BATM will provide further details on trading and its outlook for 2014 in its full year results announcement.

 

 

 

Enquiries

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Ofer Bar-Ner, Chief Financial Officer 

 

finnCap

Stuart Andrews, Henrik Persson

+44 20 7220 0500

Shore Capital

Pascal Keane

+44 20 7408 4090

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBQLLBZFFBBBX
Date   Source Headline
26th May 20267:00 amRNSBlock Listing Interim Review
21st Apr 20267:00 amRNSPublication of Annual Report
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 202612:00 pmRNSHolding(s) in Company
10th Feb 20267:00 amRNSSale of Non-core Business
3rd Feb 20267:00 amRNSHolding(s) in Company
2nd Feb 20267:00 amRNSHolding(s) in Company
19th Jan 20267:00 amRNS-RBATM selected as FPT Israel cybersecurity partner
12th Jan 20267:00 amRNSHolding(s) in Company
12th Jan 20267:00 amRNSHolding(s) in Company
8th Jan 202611:00 amRNSTransaction in own shares and Total Voting Rights
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:01 amRNSDirector Declaration
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
2nd Jan 20267:00 amRNSCompletion of Sale of Diagnostics Distributor
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
29th Dec 20257:00 amRNSAppointment of Chairman and Directorate Change
10th Dec 202512:00 pmRNSAGM Result, Directorate Change & AMS Sale Update
1st Dec 20257:00 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSBlock Listing Interim Review
17th Nov 20257:00 amRNSNew Carrier Ethernet Order
5th Nov 20257:00 amRNSNotice of AGM and Directorate Changes
6th Oct 20257:00 amRNSSale of Diagnostics Distributor
26th Sep 20257:00 amRNSDirectorate Change
18th Aug 20257:00 amRNSInterim Results
4th Aug 20257:00 amRNSTotal Voting Rights
24th Jul 20257:00 amRNSSale of Non-Core Businesses and Notice of Results
23rd Jun 20257:00 amRNSDirectorate Change
27th May 20257:00 amRNSBlock Listing Interim Review
12th May 20257:00 amRNSOrder for ultra-high speed encryption development
6th May 20257:00 amRNS-RBATM unveils new brand identity
8th Apr 202511:00 amRNSAnnual Report Publication and AGM Update Statement
27th Mar 20257:00 amRNSNew strategic customer for Edgility in Brazil
17th Mar 20257:00 amRNSFull Year Results
5th Mar 20257:00 amRNSUpdate on Strategy and Trading
24th Feb 20257:00 amRNSHolding(s) in Company
16th Jan 20257:00 amRNSADOR appoints Nadhim Zahawi to lead Advisory Board
19th Dec 20243:30 pmRNSResult of AGM and Director Appointment
19th Dec 20247:00 amRNSNew Tier 1 Customer for Edgility in Mexico
11th Dec 20247:00 amRNSNATlab commences pre-clinical validation
3rd Dec 20247:00 amRNSBlock Listing Interim Review
2nd Dec 20247:00 amRNSBATM receives orders of $2.4m for Edgility
25th Nov 20247:00 amRNSBlock listing Interim Review
14th Nov 202411:00 amRNSNotice of AGM and Proposed Director Appointment
4th Nov 20247:00 amRNSTotal Voting Rights
19th Aug 20247:00 amRNSInterim Results
10th Jul 20247:00 amRNSAmazon Web Services partnership for Edgility
2nd Jul 20247:00 amRNSCommercial markets cybersecurity partnership
3rd Jun 20247:00 amRNSBlock Listing Interim Review
28th May 20247:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.